Search results
Results From The WOW.Com Content Network
Spondyloarthritis (SpA), also known as spondyloarthropathy, is a collection of clinical syndromes that are connected by genetic predisposition and clinical manifestations. [1] The best-known clinical subtypes are enteropathic arthritis (EA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and reactive arthritis (ReA). [2]
Over a long-term period, osteopenia or osteoporosis of the AP spine may occur, causing eventual compression fractures and a back "hump". [47] Hyperkyphosis from ankylosing spondylitis can also lead to impairment in mobility and balance, as well as impaired peripheral vision, which increases the risk of falls which can cause fracture of already ...
More than 80% of patients with the ankylosing spondylitis variant test positive for the HLA-B27 biomarker, but not everyone with this biomarker will develop disease. [22] Some people with axial spondyloarthritis may test positive for elevated C-reactive protein , or CRP, depending on their disease activity. [ 22 ]
In cervical spondylosis, a patient may be presented with dull neck pain with neck stiffness in the initial stages of the disease. As the disease progresses, symptoms related to radiculopathy (due to compression of exiting spinal nerve by narrowed intervertebral foramen) or myelopathy (due to compression on the spinal cord) can occur. [2]
The BASDAI or Bath Ankylosing Spondylitis Disease Activity Index is a validated diagnostic test which allows a physician, usually a rheumatologist, to determine the effectiveness of a current drug therapy, or the need to institute a new drug therapy for the treatment of Ankylosing spondylitis (AS).
Iris Davis, who is 80 years old, sure has an impressive resume. She’s won countless fitness awards, including the Fittest Senior in the USA in 2006 by Nintendo.
1. Minoxidil. Let’s start this list off with your best option: minoxidil. The generic version of Rogaine®, minoxidil is an FDA-approved treatment available as a liquid, foam and oral medication.
The development of targeted biological treatments has had an impact on enteropathic arthritis management. Psoriatic arthritis, [32] [33] enthesopathy linked to spondyloarthropathy, [34] and refractory ankylosing spondylitis [35] can all benefit from biological blockade using the TNFa antagonists etanercept and infliximab.